Abstract
Familial hypercholesterolaemia (FH) is a common inherited condition, affecting about one in 300 people worldwide, and is characterised by elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth [1–3]. If untreated, this burden of lifelong high LDL-C levels predisposes to premature atherosclerotic cardiovascular disease (ASCVD), with individuals often experiencing their first myocardial infarction during middle-age [1]. However, if detected early – ideally during childhood – with prompt initiation of guideline-recommended lipid lowering therapy, individuals with this condition can live a normal, healthy life [4].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
